Compare
Semaglutide vs Tirzepatide
Two of the most extensively studied incretin-based therapies — approved and marketed in the same therapeutic areas, but with different receptor profiles, different phase-3 programs, and different published outcomes. This page compares what the peer-reviewed literature and regulatory documentation currently support for each.
Last reviewed 2026-07-12
Regulatory status
Semaglutide
FDA-approved: Ozempic (T2D, 2017; CV risk reduction in T2D + CVD, 2020); Wegovy (chronic weight management, 2021; CV risk reduction in overweight/obesity + CVD, 2024); Rybelsus (oral, T2D, 2019). EMA-approved for the same three brands.
Tirzepatide
FDA-approved: Mounjaro (T2D, 2022); Zepbound (chronic weight management, 2023). EMA-approved. No CV risk-reduction indication yet (SURPASS-CVOT is ongoing).
6 citations in this row
Receptor targets
Semaglutide
GLP-1 receptor mono-agonist.
Tirzepatide
Dual GLP-1 receptor and GIP receptor agonist (imbalanced and biased in favour of GIPR at the cellular level per preclinical characterisation).
2 citations in this row
Approved indications
Semaglutide
Type 2 diabetes (Ozempic, Rybelsus). Chronic weight management (Wegovy). Cardiovascular risk reduction in T2D + established CVD (Ozempic). Cardiovascular risk reduction in overweight/obesity + established CVD without diabetes (Wegovy, 2024).
Tirzepatide
Type 2 diabetes (Mounjaro). Chronic weight management (Zepbound). Investigational for CV outcomes (SURPASS-CVOT), HFpEF (SUMMIT), MASLD, and OSA.
5 citations in this row
Published head-to-head data
Semaglutide
SURPASS-2 (2021) compared semaglutide 1 mg weekly to tirzepatide 5, 10, and 15 mg weekly in adults with T2D. Semaglutide 1 mg produced smaller reductions in HbA1c and body weight than every tested tirzepatide dose at 40 weeks. NOTE: this trial does NOT compare the 2.4 mg obesity dose of semaglutide.
Tirzepatide
SURPASS-2 (2021): superior to semaglutide 1 mg at all three tested tirzepatide doses in T2D. No published head-to-head trial vs semaglutide 2.4 mg in the obesity population.
1 citation in this row
Headline efficacy in flagship obesity trials
Semaglutide
STEP-1 (2021): mean body-weight reduction of −14.9% at 68 weeks with semaglutide 2.4 mg weekly in adults with overweight/obesity without diabetes.
Tirzepatide
SURMOUNT-1 (2022): mean body-weight reduction of −20.9% at 72 weeks with tirzepatide 15 mg weekly in adults with obesity without diabetes.
2 citations in this row
Cross-trial comparison caveat
Semaglutide
STEP-1 and SURMOUNT-1 were conducted separately, with different eligibility criteria, different lead-in phases, different endpoint windows (68 vs 72 weeks), and different populations. A direct comparison of their headline percentages does not substitute for a randomised head-to-head trial at semaglutide 2.4 mg.
Tirzepatide
The same caveat applies to tirzepatide's numbers. No adequately-powered head-to-head trial vs semaglutide 2.4 mg has been published; a comparison of headline STEP-1 and SURMOUNT-1 numbers is indicative only.
2 citations in this row
Cardiovascular outcomes
Semaglutide
SUSTAIN-6 (2016) demonstrated non-inferiority and superiority for MACE reduction in adults with T2D and established CV disease or high CV risk (supports Ozempic's CV indication). SELECT (2023) demonstrated MACE reduction in adults with overweight/obesity and established CV disease WITHOUT diabetes (supports Wegovy's 2024 CV indication).
Tirzepatide
No published phase-3 cardiovascular outcomes trial. SURPASS-CVOT is ongoing; readout is expected in the next few years.
2 citations in this row
Other outcomes trials
Semaglutide
FLOW (2024) demonstrated reduced progression of chronic kidney disease in adults with T2D. STEP-HFpEF (2023) demonstrated improvement in heart-failure symptoms and body-weight outcomes in adults with HFpEF and obesity.
Tirzepatide
SUMMIT (HFpEF program) is ongoing. MASLD and obstructive sleep apnoea programs are ongoing. None have currently been translated into approved indications.
2 citations in this row
Safety-data maturity
Semaglutide
Extensive. Post-marketing surveillance ongoing since 2017 across three brands and multiple indications. GI adverse events dominate; boxed warning for thyroid C-cell tumours in rodents; SUSTAIN-6 diabetic retinopathy signal in participants with pre-existing severe DR.
Tirzepatide
Substantial and growing. Post-marketing surveillance ongoing since 2022. GI adverse events dominate; boxed warning for thyroid C-cell tumours in rodents; cholelithiasis observed in trials.
2 citations in this row
Formulation and presentation
Semaglutide
Prefilled subcutaneous pens (Ozempic multi-dose; Wegovy prefilled single-use). Oral tablet (Rybelsus) with SNAC absorption enhancer — the only oral GLP-1 approved to date. No approved reconstitution presentation.
Tirzepatide
Prefilled subcutaneous multi-dose pen. Ready-to-use — no reconstitution required in the licensed presentation. No approved oral formulation.
3 citations in this row
Dosing schedule
Semaglutide
Ozempic: 0.25 → 0.5 → 1 → 2 mg once weekly, 4-week intervals. Wegovy: 0.25 → 0.5 → 1 → 1.7 → 2.4 mg once weekly, 4-week intervals. Rybelsus: 3 → 7 → 14 mg once daily oral, 30-day intervals, empty stomach with ≤120 mL water.
Tirzepatide
2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg once weekly, 4-week intervals. Maintenance doses studied: 5, 10, and 15 mg once weekly in both SURPASS (T2D) and SURMOUNT (obesity).
5 citations in this row
Semaglutide and tirzepatide sit in the same therapeutic space with overlapping approvals but distinctly different research portfolios. Semaglutide's evidence base is broader across indications (T2D, obesity, cardiovascular risk reduction with and without diabetes, renal outcomes, HFpEF, oral formulation). Tirzepatide's evidence base in its shared indications is more recent and has shown larger effect sizes on shared endpoints (glucose, weight) in the one published head-to-head trial (at semaglutide 1 mg). Neither compound is a substitute for a clinical decision informed by an individual's medical history.
References
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)· Frías JP, Davies MJ, Rosenstock J, et al. · 2021
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)· Jastreboff AM, Aronne LJ, Ahmad NN, et al. · 2022
- Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4)· Aronne LJ, Sattar N, Horn DB, et al. · 2024
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)· Wilding JPH, Batterham RL, Calanna S, et al. · 2021
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial· Rubino D, Abrahamsson N, Davies M, et al. · 2021
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial· Garvey WT, Batterham RL, Bhatta M, et al. · 2022
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial· Rubino DM, Greenway FL, Khalid U, et al. · 2022
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)· Marso SP, Bain SC, Consoli A, et al. · 2016
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)· Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · 2023
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW)· Perkovic V, Tuttle KR, Rossing P, et al. · 2024
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)· Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. · 2023
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial· Rosenstock J, Allison D, Birkenfeld AL, et al. · 2019
- FDA Prescribing Information — OZEMPIC (semaglutide) injection· U.S. Food and Drug Administration · 2017
- FDA Prescribing Information — WEGOVY (semaglutide) injection· U.S. Food and Drug Administration · 2021
- FDA Prescribing Information — RYBELSUS (semaglutide) tablets· U.S. Food and Drug Administration · 2019
- FDA Prescribing Information — MOUNJARO (tirzepatide) injection· U.S. Food and Drug Administration · 2022
- FDA Prescribing Information — ZEPBOUND (tirzepatide) injection· U.S. Food and Drug Administration · 2023
- Ozempic (semaglutide) — European Public Assessment Report (EPAR)· European Medicines Agency · 2018
- Mounjaro (tirzepatide) — European Public Assessment Report (EPAR)· European Medicines Agency · 2022
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide· Lau J, Bloch P, Schäffer L, et al. · 2015
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist· Willard FS, Douros JD, Gabe MBN, et al. · 2020
Continue exploring
Editorial paths through the library. Pick one and follow the trail.
Compare
Tirzepatide vs Retatrutide
Two incretin-based peptides in the same broad family, but at very different stages of development. This page compares what the peer-reviewed literature currently supports on each — regulatory status, receptor targets, evidence tier, and headline efficacy from published phase-3 trials.
→
Compare
BPC-157 vs TB-500
These two peptides are the most-discussed pair in the tissue-repair conversation, and they are also the most-conflated. In practice they share none of what usually justifies grouping compounds: their origins are unrelated, their mechanisms are unrelated, and the shape of the evidence supporting each is structurally different. This page walks through those distinctions.
→
Compare
KPV vs GHK-Cu
Two small, endogenously-derived peptides that get grouped in discussions about anti-inflammatory and skin peptides. They share molecular scale — both are tripeptides — and their mechanisms are both proposed to be intracellular rather than classical receptor-mediated. Everything else about their evidence structures, use cases, and regulatory status differs, in ways that are worth reading precisely.
→
Compare
Tesamorelin vs Sermorelin
Two GHRH analogues built for the same fundamental job — stimulating the pituitary's own pulsatile release of growth hormone — but at very different points in structure, half-life, and regulatory history. This page compares what the peer-reviewed literature and regulatory documentation currently support for each.
→
Compare
CJC-1295 (No DAC) vs Sermorelin
Two GHRH(1-29)-based signals. Sermorelin is the native sequence; CJC-1295 No DAC is the same sequence with four amino acid substitutions that resist enzymatic degradation. This page compares what the peer-reviewed literature currently supports on each.
→
Compare
CJC-1295 No DAC vs CJC-1295 DAC
The two forms share an identical GHRH(1-29) backbone with the same four amino acid substitutions. The Drug Affinity Complex (DAC) — a single maleimidopropionic acid linker that covalently binds serum albumin — is the only chemical difference. Every downstream pharmacologic property flows from that one addition. This page reads out those differences precisely.
→
Compare
AOD-9604 vs Semaglutide
Two compounds pursued as pharmacological approaches to weight loss, from opposite starting points and with opposite clinical results. AOD-9604 was designed as a lipolytic fragment of human growth hormone; its 2007 phase 2b did not meet its primary endpoint and its pharmaceutical program was discontinued. Semaglutide came from the incretin research tradition, obtained FDA approval for chronic weight management in 2021, and produced a large clinical evidence base. This page presents the two side by side to make each visible in the other's context.
→
Categories
Fat Loss & Metabolism
Compounds studied for body-composition, glycaemic control, and metabolic health.
→
Categories
Repair & Regeneration
Compounds studied for wound healing, tissue repair, and musculoskeletal recovery.
→